Corcept executive exercises options, sells 20,305 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
On 2026-08-03, Corcept Therapeutics executive Sean Maduck exercised stock options for 20,305 shares of common stock at $8.27 per share and sold the same number of shares at a weighted average price of $114.7045 (range $114.49–$115.00), pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. He continues to hold 96,681 stock options and additional common stock, including unvested restricted stock awards and indirect holdings through trusts and LLCs.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F9 | 20,305 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 20,305 | $8.27 | $168K |
| Sale | Common Stock F2, F3, F1 | 20,305 | $114.7045 | $2.33M |
| Holding | Common Stock F4 | -- | -- | -- |
| Holding | Common Stock F5 | -- | -- | -- |
| Holding | Common Stock F6 | -- | -- | -- |
| Holding | Common Stock F7 | -- | -- | -- |
| Holding | Common Stock F8 | -- | -- | -- |
Footnotes (9)
- F1. Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
- F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.49 to $115.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
- F5. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
- F6. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F7. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F8. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- F9. Fully exercisable.
Key Figures
Key Terms
Rule 10b5-1 plan regulatory
Grantor Retained Annuity Trust financial
weighted average sale price financial
restricted stock awards financial
pecuniary interest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Corcept Therapeutics (CORT) executive Sean Maduck report in this Form 4?
Was Sean Maduck’s CORT stock sale made under a Rule 10b5-1 plan?
How many Corcept Therapeutics (CORT) stock options does Sean Maduck hold after this transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.